Seroresponse to trivalent oral poliovirus vaccine as a function of dosage interval.
Seroresponses to trivalent oral poliovirus vaccine are not uniform throughout the world. Definition of the variables that determine successful immunization is vital to ensure global polio eradication. One such variable may be dosage interval. To investigate this effect 108 infants were enrolled in a clinical trial and randomly assigned to receive three doses of trivalent oral poliovirus vaccine (standard United States formulation) at 2, 3 and 4 or 2, 4 and 6 months of age. After three doses of vaccine given before 6 months of age, immunity was virtually complete for each of the three poliovirus types in both groups. After two doses the seroresponse rate to each type was less with the shorter dose interval. However the difference was not significant (P = 0.15) in the sample size studied. Such responses differ markedly from those seen in developing countries, where four or more doses of vaccine may fail to provide complete protection. Differences other than dosage interval must contribute to those failures.
Cohen-Abbo
A
A
Department of Pediatrics, Vanderbilt University Medical Center, Nashville, TN 37232-2581, USA.
Culley
B S
BS
Reed
G W
GW
Sannella
E C
EC
Mace
R L
RL
Robertson
S E
SE
Wright
P F
PF
D000914:Antibodies, Viral / Q000096:biosynthesis*; D004305:Dose-Response Relationship, Drug; D005243:Feces / Q000821:virology; D006801:Humans; D007115:Immunization Schedule; D007223:Infant; D011051:Poliomyelitis / Q000276:immunology / Q000517:prevention & control; D017955:Poliovirus / Q000276:immunology / Q000302:isolation & purification; D011055:Poliovirus Vaccine, Oral / Q000008:administration & dosage* / Q000276:immunology*; D014611:Vaccination; D017201:Virus Shedding
D000914:Antibodies, Viral; D011055:Poliovirus Vaccine, Oral